Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

North Chicago, Illinois-based AbbVie Inc. (ABBV) focuses on creating medicines and solutions that address complex health issues and enhance people's lives through its core therapeutic areas ...

Berenberg Bank analyst Richard Hatch maintained a Hold rating on AbbVie (ABBV – Research Report) yesterday and set a price target of $165.00.

AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time.

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie, Inc. is a research-based biopharmaceutical ... The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.